formulations referred to, the MAPE exceeds 300%. The price increase in respect of these formulations also has not been more than 100% during 1991-92;

(b) To the extent available, required information is given in the enclosed Statement-1. (*see below*) Form 2A in respect of all the five formulations has been received from the concerned companies.

(c) Requisite information is given in the enclosed Statement-2.

Statement

Formulation	Pack size	Company	Price as in March. 92 (Rs.)	Current price (Rs.)	Sales turnover (Rs.)
1	2	3	4	5	6
Betaloc Inj.	5×5ml	Astra IDL	12.38	12.64	10.614 (91-92)
Calcium Sandoz Syp.	200ml	Sandoz	22.00 (Feb. 92)	Pack discontinued after Feb. 92	12,48,000 (1991)
Pethidine Inj.	10Amp.	Alembic	33.00	33.00	67,812 (1990-91)
Corbetta Tabs.	10's	Sarabhai Chemicals	3.30	3.53	N.A.
Pondres 20mg.	10×10	Serdia Pharma	198.72	265.46	31,75,000 (1991-92)
-do- 60mg.	10's	-do-	61.16	81.75	91,98,000 (1991-92)

Statement-2

Name of non-scheduled formulations in which cases the Prices have been reduced:

Name of the formulations	Pack Size	Name of Company	Price fixed by the Co. (Rs.)	Reduced price after Govt. intervention (Rs.)	Effective date/ Batch)
Insulin Pain 40 unit	10ml	Boots Pharma	29.80	27.80	Batch No. 21B.
Insulin lents 40 unit	10ml		29.80	27.80	Batch No. 38B
Insulin NPH 40 unit	10ml		29.80	27.80	Batch No. 6B
Insulin PZ 40 unit	10ml		30.50	28.50	Batch No. 2B

Sharp Increase in Prices of Decontrolled Medicines

391. SHRIMATI KAILASH PATI:
SHRI RAJNI RANJAN SAHU:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question No. 1607 given in Rajya Sabha on 3rd December, 1992 and state:

(a) whether it is a fact that all the twelve formulation packs have registered price increase between 100 per cent to 300 per cent and the MAPE taken by the formulations is 500 to 600 per cent;

(b) whether it is a fact that these twelve formulations account for a sales turn over of more than Rs. 140 crores Per annum;

(c) what was the composition of the sample which revealed that only in 12 to 13 per cent of the cases MAPE taken is more than 100 per cent and what were the products included in the sample;

(d) what were their earlier prices with MAPE and what are their revised prices with MAPE; and

(e) what is the rate of major bulk drug taken into consideration in each case and how it is assured that material and other costs have not been overcharged?

THE MINISTER OF STATE IN THE MINISTTY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) To the extent available, information on % increase of price and MAPE has already been indicated in Columns 8 and 9 of the Statement enclosed with the reply to the Rajya Sabha Unstarred Question No. 1607 dated 3.12.92.

(b) No. Sir.

(c) to (e) As replied in part (a) of the Rajya Sabha Unstarred Question No. 1607 dated 3.12.92, the price increase,

and not MAPE, recorded an increase of more than 100% over the prices prevailing at the time of announcement of DPCO, 87 in 12 to 13 percent cases. The sample included some 700 formulation packs based on more than 100 bulk drugs. Time and labour involved in collecting and compiling this information would not be commensurate with the results likely to be achieved.

Production of Dilantin

392. SHRI GURUDAS DAS GUPTA:
SHRI N.E. BALARAM:

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that a multi-national drug company has stopped producing Dilantin, a drug used for treating apilepsy; and

(b) if so, the details thereof and the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) M/s. Parke-Davis, the producers of Dilantin, have informed that they have temporarily discontinued the manufacture of Dilantin Capsules due to some technical problems.

Liabilities against M/s. Synbiotics

393. SHRI RAJNI RANJAN SAHU:
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to state:

(a) whether there is any liability against M/s Synbiotics in respect of Streptomycin, if so, the amount assessed and what is the present position;

(b) whether there is any court stay to the determination of liability in respect of Streptomycin; and

(c) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (c) a notice for recovery of the difference between the pooled price and the retention price of Streptomycin was sent to M/s Synbiotics on 10th June, 1980 against which the company has filed a Writ petition in the Delhi High Court in 1981 and has got a stay order, of the demand made by the Government and the Court has also restrained any corrective step being taken regarding enforcement of the impugned order. This Writ Petition has not been heard by the Delhi High Court since 1981.

Fixation of market prices of drugs

394. DR. NARREDDY THULASI REDDY: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1609 given in Rajya Sabha on 3rd December, 1992 and state:

(a) whether instances of market price being lower than the Government fixed price in respect of four drugs and producers defying Government fixed prices of formulations have come to the notice of this Ministry;

(b) if so, the details thereof;

(c) whether it is a fact that even the reduction in approved price of formulations by the competent authority was not announced thereby giving benefit to the producers;

(d) if so, the details of such instances giving the strength, pack of each product and the names of producers; and

(c) what steps were taken to investigate the matter and fix responsibility?

THE MINISTER OF STATE IN THE MINISTERY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) The price notified by the Government in respect of any bulk drug, including the four bulk drugs mentioned in answer to Rajya Sabha Unstarred Question No. 1609, is the maximum price at which the drug can be marketed and sale at prices lower than